Guanfacine Extended-release Tablet, Extended Release
Product Images NDC 71335-3078

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine Extended-release (NDC 71335-3078). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph comparing guanfacine plasma concentration (ng/mL) over 24 hours for extended-release and immediate-release guanfacine, both at 1 mg QD. The x-axis represents time in hours and the y-axis shows plasma concentration levels. Extended-release guanfacine shows a gradual increase and sustained plasma concentration, while immediate-release guanfacine peaks sharply early and declines thereafter.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A chart showing fold changes and 90% confidence intervals in pharmacokinetic parameters (Cmax and AUC) of Guanfacine extended-release when co-administered with various CYP3A4/5 inhibitors and inducers. The chart compares data for ketoconazole, fluconazole, rifampin, efavirenz, oral methylphenidate, and lisdexamfetamine dimesylate, with fold changes relative to reference values on the x-axis from 0 to 5.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A chart showing fold change and 90% confidence intervals in pharmacokinetic parameters (Cmax and AUC) for interacting drugs oral methylphenidate and lisdexamfetamine dimesylate. The horizontal axis represents change relative to reference, ranging from 0.0 to 2.0, with data points near 1.0 indicating minimal change.*
FDA Label Image

Figure4.jpg (Figure4)

Figure4.jpg (Figure4)
A line graph comparing treatment failure over time between placebo and SPD503 groups. The x-axis represents time to treatment failure in days, the y-axis shows the percentage of treatment failure. The solid line indicates placebo, and the dashed line indicates SPD503, with treatment failure increasing over time for both.*
FDA Label Image

Label (Lbl713353078)

Label (Lbl713353078)
Label for guanfacine extended-release tablets showing a strength of 1 mg per tablet. The package contains 30 tablets, labeled as prescription only. The label includes manufacturer Apotex Inc. and repackager Bryant Ranch Prepack, Inc. It lists storage instructions and a QR code for the package insert. NDC 71335-3078-1 is displayed along with barcodes.*
FDA Label Image

Spd503-chemical-stucture (Spd503 Chemical Stucture)

Spd503-chemical-stucture (Spd503 Chemical Stucture)
Chemical structure of guanfacine hydrochloride, the active ingredient in Guanfacine extended-release tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.